Woman in laboratory


Using personalised medicine to detect and treat pancreatitis and pancreatic cancer

The European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC) is an internationally-renowned academic, collaborative study involving pancreas specialists from the University of Liverpool and across Europe in addressing global health issues of pancreatic diseases, which present some of the most critical of unmet clinical needs.

Pancreatic cancer alone accounts for 250,000 deaths each year worldwide and it is predicted to become the second highest cause of cancer death in the UK by 2020. There are more than 25,000 cases of acute pancreatitis recorded each year in the UK alone, causing more than 2,000 deaths.

Chronic pancreatitis is less common and less often fatal but is extremely debilitating and affects approximately 50 out of every 100,000 people in the UK. These numbers are impressive and depressing, but are dwarfed by the more than 3,000,000 UK citizens with diabetes mellitus.

EUROPAC offers hope of improved treatment and detection for all of these diseases, but perhaps of more immediate impact offers a point of contact for individuals who are aware of their inherited risk and need support in managing their anxiety.

How you can help

The EUROPAC team are constantly working to improve the methods by which they carry out cancer screening, in the hope that one-day it will advance to the point where potentially lifesaving screens can be offered to a wider range of people. We are also looking at data such as environmental and lifestyle factors which may influence pancreatic cancer development. Donations to the EUROPAC fund would allow them to continue and accelerate this work.

Their financial target is to collect £100,000 per year, or roughly the amount of money it takes to image 150 people.

Make a gift to the EUROPAC fund today.

Back to: Giving